Leprosy is a chronic infectious disease caused by Mycobacterium leprae, an acid-fast, rod-shaped bacillus. The disease mainly affects the skin, the peripheral nerves, mucosa of the upper respiratory tract and also the eyes, apart from some other structures.
Leprosy is curable and treatment provided in the early stages averts disability.
Multidrug therapy (MDT) treatment has been made available by WHO free of charge to all patients worldwide since 1995, and provides a simple yet highly effective cure for all types of leprosy.
According to official reports received from 121 countries and territories, the global registered prevalence of leprosy at the beginning of 2009 stood at 213 036 cases, while the number of new cases detected during 2008 was 249 007. The number of new cases detected globally has fallen by 9126 (a 4% decrease) during 2008 compared with 2007.
Pockets of high endemicity still remain in some areas of Angola, Brazil, Central African Republic, Democratic Republic of Congo, India, Madagascar, Mozambique, Nepal, and the United Republic of Tanzania. These countries remain highly committed to eliminating the disease, and continue to intensify their leprosy control activities.
Although leprosy was treated differently in the past, the first breakthrough occurred in the 1940s with the development of the drug dapsone, which arrested the disease. But the duration of the treatment was many years, even a lifetime, making it difficult for patients to follow. In the 1960s, M. leprae started to develop resistance to dapsone, the world’s only known anti-leprosy drug at that time. In the early 1960s, Rifampicin and clofazimine, the other two components of MDT, were discovered.
In 1981, a World Health Organization (WHO) Study Group recommended multidrug therapy (MDT). MDT consists of 3 drugs: dapsone, rifampicin and clofazimine and this drug combination kills the pathogen and cures the patient.
Since 1995, WHO provides free MDT for all patients in the world, initially through the drug fund provided by the Nippon Foundation and since 2000, through the MDT donation provided by Novartis and the Novartis Foundation for Sustainable Development.
The age-old stigma associated with the disease remains an obstacle to self-reporting and early treatment. The image of leprosy has to be changed at the global, national and local levels. A new environment, in which patients will not hesitate to come forward for diagnosis and treatment at any health facility, must be created.
Source:
http://who.int
Selengkapnya →
Leprosy is curable and treatment provided in the early stages averts disability.
Multidrug therapy (MDT) treatment has been made available by WHO free of charge to all patients worldwide since 1995, and provides a simple yet highly effective cure for all types of leprosy.
 |
| Click to Zoom In... |
Leprosy today
The diagnosis and treatment of leprosy today is easy and most endemic countries are striving to fully integrate leprosy services into existing general health services. This is especially important for those under-served and marginalised communities most at risk from leprosy, often the poorest of the poor.According to official reports received from 121 countries and territories, the global registered prevalence of leprosy at the beginning of 2009 stood at 213 036 cases, while the number of new cases detected during 2008 was 249 007. The number of new cases detected globally has fallen by 9126 (a 4% decrease) during 2008 compared with 2007.
Pockets of high endemicity still remain in some areas of Angola, Brazil, Central African Republic, Democratic Republic of Congo, India, Madagascar, Mozambique, Nepal, and the United Republic of Tanzania. These countries remain highly committed to eliminating the disease, and continue to intensify their leprosy control activities.
Brief history
Disease and Treatment
Leprosy was recognized in the ancient civilizations of China, Egypt and India. The first known written mention of leprosy is dated 600 BC. Throughout history, the afflicted have often been ostracized by their communities and families.Although leprosy was treated differently in the past, the first breakthrough occurred in the 1940s with the development of the drug dapsone, which arrested the disease. But the duration of the treatment was many years, even a lifetime, making it difficult for patients to follow. In the 1960s, M. leprae started to develop resistance to dapsone, the world’s only known anti-leprosy drug at that time. In the early 1960s, Rifampicin and clofazimine, the other two components of MDT, were discovered.
In 1981, a World Health Organization (WHO) Study Group recommended multidrug therapy (MDT). MDT consists of 3 drugs: dapsone, rifampicin and clofazimine and this drug combination kills the pathogen and cures the patient.
Since 1995, WHO provides free MDT for all patients in the world, initially through the drug fund provided by the Nippon Foundation and since 2000, through the MDT donation provided by Novartis and the Novartis Foundation for Sustainable Development.
Elimination of leprosy as a public health problem
In 1991 WHO's governing body, the World Health Assembly (WHA) passed a resolution to eliminate leprosy as a public health problem by the year 2000. Elimination of leprosy as a public health problem is defined as a prevalence rate of less than one case per 10 000 persons. The target was achieved on time and the widespread use of MDT reduced the disease burden dramatically.- Over the past 20 years, more than 14 million leprosy patients have been cured, about 4 million since 2000.
- The prevalence rate of the disease has dropped by 90% – from 21.1 per 10 000 inhabitants to less than 1 per 10 000 inhabitants in 2000.
- Dramatic decrease in the global disease burden: from 5.2 million in 1985 to 805 000 in 1995 to 753 000 at the end of 1999 to 213 036 cases at the end of 2008.
- Leprosy has been eliminated from 119 countries out of 122 countries where the disease was considered as a public health problem in 1985.
- So far, there has been no resistance to antileprosy treatment when used as MDT.
- Efforts currently focus on eliminating leprosy at a national level in the remaining endemic countries and at a sub-national level from the others.
Actions and resources required
In order to reach all patients, treatment of leprosy needs to be fully integrated into general health services. This is a key to successful elimination of the disease. Moreover, political commitment needs to be sustained in countries where leprosy remains a public health problem. Partners in leprosy elimination also need to continue to ensure that human and financial resources are made available for the elimination of leprosy.The age-old stigma associated with the disease remains an obstacle to self-reporting and early treatment. The image of leprosy has to be changed at the global, national and local levels. A new environment, in which patients will not hesitate to come forward for diagnosis and treatment at any health facility, must be created.
Strategy for leprosy elimination
The following actions are part of the ongoing leprosy elimination campaign:- ensuring accessible and uninterrupted MDT services available to all patients through flexible and patient-friendly drug delivery systems;
- ensuring the sustainability of MDT services by integrating leprosy services into the general health services and building the ability of general health workers to treat leprosy;
- encouraging self-reporting and early treatment by promoting community awareness and changing the image of leprosy;
- monitoring the performance of MDT services, the quality of patients’ care and the progress being made towards elimination through national disease surveillance systems.
Source:
http://who.int
